Joint health showdown: which hemophilia a therapy wins?
NCT ID NCT04690322
First seen Apr 09, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study was designed to compare two standard treatments for severe or moderate hemophilia A: extended half-life factor VIII therapy and non-factor VIII therapy. Researchers planned to use ultrasound and blood tests to see which treatment better protects joints and prevents bleeding in children under 18. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75235, United States
Conditions
Explore the condition pages connected to this study.